media – Page 412 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Big news! Hengrui ADC innovative drug SHR-A1811 new indication to be included in breakthrough therapy species

Recently, Hengrui Medicine’s ADC innovative drug SHR-A1811 for the treatment of HER2-mutated advanced non-small cell lung cancer who failed previous platinum-based chemotherapy was proposed to be included in the public list of breakthrough therapy varieties by the Center for Drug Evaluation of the National Medical Products Administration. The study was led by Professor Lu Shun from the Chest Hospital Affiliated to Shanghai Jiaotong University, and a total of 10 centers across the country participated. At the same time, the other two indications of SHR-A1811 have been included in the list of breakthrough therapy varieties by the Drug Evaluation Center of the State Drug Administration in February this year. The indications are: low expression of human epidermal growth factor receptor 2 (HER2). Recurrent or metastatic breast cancer and human epidermal growth factor receptor 2 (HER2) positive recurrent or metastatic breast cancer. Lung cancer is currently the leading cause of cancer-related death ...
- Source: drugdu
- 143
- March 20, 2023
The high price of Ozempic is pushing many to unregulated, copycat drugs for weight loss

Some compounding pharmacies are offering what they say are generic versions of the drugs, which have soared in popularity for weight loss. When Robin Langois, 58, was prescribed the weight-loss drug Wegovy last year, she couldn’t afford the high price tag after her insurance wouldn’t cover it. But she later discovered on TikTok that people could get their hands on what appeared to be the drug’s active ingredient, semaglutide, from compounding pharmacies for a fraction of the price. Langois, of Tucson, Arizona, said she was initially hesitant, because of safety concerns, but she eventually found a telehealth provider to write her a prescription. “I’m not 100% sure it’s what I’m getting,” Langois said. She noted, however, that she’s experienced feelings of fullness and weight loss, as well as nausea, a common side effect of the drug. “It’s working like it should,” she said. Either due to cost or ongoing shortages, ...
- Source: drugdu
- 168
- March 20, 2023
UBS buys Credit Suisse for $3.2 billion as regulators look to shore up the global banking system

The Financial Times reported that UBS has agreed to buy the bank for more than $2 billion, a substantial increase from the initial $1 billion offer it reported earlier Sunday. UBS agreed to buy its embattled rival Credit Suisse for $3.2 billion Sunday, with Swiss regulators playing a key part in the deal as governments looked to stem a contagion threatening the global banking system. “With the takeover of Credit Suisse by UBS, a solution has been found to secure financial stability and protect the Swiss economy in this exceptional situation,” read a statement from the Swiss National Bank, which noted the central bank worked with the Swiss government and the Swiss Financial Market Supervisory Authority to bring about the combination of the country’s two largest banks. The terms of the deal will see Credit Suisse shareholders receive 1 UBS share for every 22.48 Credit Suisse shares they hold. “This ...
- Source: drugdu
- 196
- March 20, 2023
Organoid Intelligence

Researchers just announced a plan to eventually create “organoid intelligence,” or OI. They plan to grow clumps of brain cells called organoids and create technology that would allow us to turn those clumps of cells into powerful and efficient computers. The technology is only in its infancy, but it has implications for everything from computer memory to neurological diagnostics. The human brain is a wonderful and complicated organ. Despite decades of study and scientific progress, there’s still a lot we don’t know about how it works and why it behaves the way it does. But we know it’s powerful. It might not be as quick to solve complex equations as a computer, but it’s wildly more energy-efficient and significantly better at both learning and memory. And recently, researchers have been looking into how combine a brain and a computer, giving us the power of a human mind at our fingertips. ...
- Source: drugdu
- 128
- March 20, 2023
New Study Shows Promising Results for Targeted Cancer Therapy

A recent study published in the Journal of Clinical Oncology has shown promising results for a new type of cancer therapy. The therapy, known as a targeted therapy, uses drugs that specifically target the genetic mutations that drive the growth of cancer cells. Traditional cancer treatments like chemotherapy and radiation therapy are often associated with serious side effects because they damage healthy cells along with cancer cells. Targeted therapies, on the other hand, are designed to be more precise and have fewer side effects. The new study focused on a targeted therapy called larotrectinib, which is designed to treat cancers that have a specific genetic mutation called NTRK fusion. NTRK fusion is a rare but important genetic alteration that is found in a variety of cancers, including certain types of lung, colon, and breast cancer. The study included 55 patients with NTRK fusion-positive cancer who were treated with larotrectinib. The ...
- Source: drugdu
- 177
- March 20, 2023
New Study Shows Potential for Personalized Treatment for Lung Cancer

Lung cancer is a leading cause of cancer-related death worldwide, and treatment options are limited for patients with advanced disease. However, a recent study published in the journal Nature has shown promising results for a new approach to treating lung cancer using personalized medicine. The researchers analyzed the genomes of more than 2,000 patients with non-small cell lung cancer and identified several genetic mutations that were associated with a better response to immunotherapy, a type of cancer treatment that helps the immune system fight cancer. The researchers also developed a personalized treatment algorithm that took into account the genetic mutations of each patient’s tumor. They found that patients who received personalized treatment based on their tumor’s genetic profile had a better response to immunotherapy than those who received standard treatment. The lead author of the study, Dr. Trever Bivona, said that the results were “very promising” and showed that personalized ...
- Source: drugdu
- 163
- March 20, 2023
New Study Shows Potential for Gene Therapy to Treat Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a rare and devastating genetic disorder that causes progressive muscle weakness and eventually leads to death. There is currently no cure for DMD and available treatments only offer modest benefits. However, a recent study published in the journal Nature has shown promising results for a new approach to treating DMD using gene therapy. The researchers used a viral vector to deliver a functional copy of the dystrophin gene, which is mutated in DMD, to muscle cells in mice with the disease. The researchers found that the gene therapy led to an improvement in muscle strength and function in the mice. They also found that the therapy was safe and well-tolerated. The lead author of the study, Dr. Dongsheng Duan, said that the results were “very encouraging” and showed that gene therapy could be a viable option for treating DMD. “This study demonstrates that gene therapy ...
- Source: drugdu
- 171
- March 20, 2023
Researchers Identify Potential New Drug Target for Treating Depression

Depression is a common and debilitating mental illness that affects millions of people worldwide. While there are several effective treatments for depression, many patients do not respond to these treatments or experience side effects. A recent study published in the journal Nature Communications has identified a potential new drug target for treating depression. The researchers focused on a protein called L-type calcium channel α1D, which plays a key role in the regulation of mood-related behaviors. Using a mouse model of depression, the researchers found that blocking the activity of this protein led to an improvement in depressive symptoms. They also found that the protein was overactive in the brains of depressed mice and in post-mortem brain tissue from people with depression. The lead author of the study, Dr. Jian Feng, said that the results were “exciting” and showed that targeting this protein could be a promising new approach to treating ...
- Source: drugdu
- 127
- March 20, 2023
NICE questions value and efficacy of five Covid-19 drugs with rejection

This week, NICE rejected five major Covid-19 therapies due to high costs and uncertainties in clinical evidence. The UK’s National Institute for Health and Care Excellence (NICE) has published a draft guidance that does not recommend the use of five major Covid-19 therapies. This news came as many organisations and patient advocacy groups have been campaigning for the adoption of some of the rejected drugs for several months, amidst concerns about access to medicines in the UK. The therapies with a negative appraisal included three anti-Covid-19 antibodies; Regeneron Pharmaceuticals’ Ronapreve (casirivimab +imdevimab), GSK’s Xevudy (sotrovimab) and, AstraZeneca’s Evusheld (tixagevimab + cilgavimab). Between November 5 and November 12, a total of 20,588 people have reported testing positive for Covid-19 in England, according to government data. This number is likely an underestimation given the lack of testing amongst the population. Furthermore, in that same period, 3,407 patients were admitted to a hospital in the country for severe cases of Covid-19. ...
- Source: drugdu
- 152
- March 17, 2023
Discovery programme launched by Cystic Fibrosis Syndicate

Aim for participants will be to quickly new antimicrobial therapies to treat chronic respiratory infections The Cystic Fibrosis (CF) Syndicate in Antimicrobial Resistance (AMR) has announced pivotal £3m funding for a Collaborative Discovery Programme. The initiative is designed to encourage drug discovery innovators in the development of new treatments for individuals with CF. Funded by medical research charity LifeArc, the programme will support approximately five collaborative projects – each receiving £500,000 of funding. The aim for participants is to quickly establish new antimicrobial therapies to treat chronic respiratory infections. Researchers within small and medium enterprises (SMEs) and academia across the world are eligible to apply, with projects expected to last up to two years. Applicants are requested to address patients’ priorities for improving treatment set out in the CF AMR Syndicate’s recently-published ‘Target Product Profiles for Antimicrobials’. The programme also delivers a collaborative approach to drug development, with successful applicants ...
- Source: drugdu
- 131
- March 17, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.